Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 200

1.

A personalized platform identifies trametinib plus zoledronate for a patient with KRAS-mutant metastatic colorectal cancer.

Bangi E, Ang C, Smibert P, Uzilov AV, Teague AG, Antipin Y, Chen R, Hecht C, Gruszczynski N, Yon WJ, Malyshev D, Laspina D, Selkridge I, Rainey H, Moe AS, Lau CY, Taik P, Wilck E, Bhardwaj A, Sung M, Kim S, Yum K, Sebra R, Donovan M, Misiukiewicz K, Schadt EE, Posner MR, Cagan RL.

Sci Adv. 2019 May 22;5(5):eaav6528. doi: 10.1126/sciadv.aav6528. eCollection 2019 May.

2.

Real-time PCR HPV genotyping in fine needle aspirations of metastatic head and neck squamous cell carcinoma: Exposing the limitations of conventional p16 immunostaining.

El-Salem F, Mansour M, Gitman M, Miles BA, Posner MR, Bakst RL, Genden EM, Westra WH.

Oral Oncol. 2019 Mar;90:74-79. doi: 10.1016/j.oraloncology.2019.02.006. Epub 2019 Feb 7.

PMID:
30846180
3.

Extracapsular extension is associated with worse distant control and progression-free survival in patients with lymph node-positive human papillomavirus-related oropharyngeal carcinoma.

Shevach J, Bossert A, Bakst RL, Liu J, Misiukiewicz K, Beyda J, Miles BA, Genden E, Posner MR, Gupta V.

Oral Oncol. 2017 Nov;74:56-61. doi: 10.1016/j.oraloncology.2017.09.014. Epub 2017 Sep 23.

PMID:
29103752
4.

Human papillomavirus (HPV) 16 antibodies at diagnosis of HPV-related oropharyngeal cancer and antibody trajectories after treatment.

Zhang Y, Waterboer T, Haddad RI, Miles BA, Wentz A, Gross ND, Fakhry C, Quon H, Lorch JH, Gourin CG, Clayburgh D, Misiukiewicz KJ, Richmon JD, Andersen PE, Posner MR, D'Souza G.

Oral Oncol. 2017 Apr;67:77-82. doi: 10.1016/j.oraloncology.2017.02.004. Epub 2017 Feb 15.

5.

Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.

Huang J, Fogg M, Wirth LJ, Daley H, Ritz J, Posner MR, Wang FC, Lorch JH.

Cancer. 2017 Jul 15;123(14):2642-2650. doi: 10.1002/cncr.30541. Epub 2017 Feb 21.

6.

A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Jimeno A, Posner MR, Wirth LJ, Saba NF, Cohen RB, Popa EC, Argiris A, Grossmann KF, Sukari A, Wilson D, Zhang X, Sun J, Glasser C, Attie KM, Sherman ML, Pandya SS, Weiss J.

Cancer. 2016 Dec 1;122(23):3641-3649. doi: 10.1002/cncr.30317. Epub 2016 Sep 20.

7.

Racial disparities in incidence of human papillomavirus-associated oropharyngeal cancer in an urban population.

Ramer I, Varier I, Zhang D, Demicco EG, Posner MR, Misiukiewicz K, Genden EM, Miles BA, Teng MS, Sikora AG.

Cancer Epidemiol. 2016 Oct;44:91-95. doi: 10.1016/j.canep.2016.07.004. Epub 2016 Aug 9.

PMID:
27518158
8.

Acupuncture for Chemoradiation Therapy-Related Dysphagia in Head and Neck Cancer: A Pilot Randomized Sham-Controlled Trial.

Lu W, Wayne PM, Davis RB, Buring JE, Li H, Macklin EA, Lorch JH, Burke E, Haddad TC, Goguen LA, Rosenthal DS, Tishler RB, Posner MR, Haddad RI.

Oncologist. 2016 Dec;21(12):1522-1529. Epub 2016 Aug 10.

9.

Overcoming the Constraints of Anti-HIV/CD89 Bispecific Antibodies That Limit Viral Inhibition.

Yu X, Duval M, Gawron M, Posner MR, Cavacini LA.

J Immunol Res. 2016;2016:9425172. doi: 10.1155/2016/9425172. Epub 2016 Jun 22.

10.

Pathogenicity and Epitope Characteristics Do Not Differ in IgG Subclass-Switched Anti-Desmoglein 3 IgG1 and IgG4 Autoantibodies in Pemphigus Vulgaris.

Lo AS, Mao X, Mukherjee EM, Ellebrecht CT, Yu X, Posner MR, Payne AS, Cavacini LA.

PLoS One. 2016 Jun 15;11(6):e0156800. doi: 10.1371/journal.pone.0156800. eCollection 2016.

11.

Clinical characteristics and outcomes of oropharyngeal carcinoma related to high-risk non-human papillomavirus16 viral subtypes.

Varier I, Keeley BR, Krupar R, Patsias A, Dong J, Gupta N, Parasher AK, Genden EM, Miles BA, Teng M, Bakst RL, Gupta V, Misiukiewicz KJ, Chiao EY, Scheurer ME, Laban S, Zhang D, Ye F, Cui M, Demicco EG, Posner MR, Sikora AG.

Head Neck. 2016 Sep;38(9):1330-7. doi: 10.1002/hed.24442. Epub 2016 Apr 15.

PMID:
27080140
12.

Clinical Outcomes in Patients with Recurrent or Metastatic Human Papilloma Virus-positive Head and Neck Cancer.

Dang RP, LE VH, Miles BA, Teng MS, Genden EM, Bakst RL, Gupta V, Zhang DY, Demicco EG, Posner MR, Misiukiewicz KJ.

Anticancer Res. 2016 Apr;36(4):1703-9.

PMID:
27069149
13.

Prognostic value of radiographic extracapsular extension in locally advanced head and neck squamous cell cancers.

Liu JT, Kann BH, De B, Buckstein M, Bakst RL, Genden EM, Posner MR, Som PM, Gupta V.

Oral Oncol. 2016 Jan;52:52-7. doi: 10.1016/j.oraloncology.2015.11.008. Epub 2015 Nov 19.

PMID:
26728104
14.

Human papillomavirus and induction chemotherapy versus concurrent chemoradiotherapy in locally advanced oropharyngeal cancer: The Dana Farber Experience.

Lorch JH, Hanna GJ, Posner MR, O'Neill A, Thotakura VL, Limaye SA, Rabinowits G, Sher DJ, Tishler RB, Haddad RI.

Head Neck. 2016 Apr;38 Suppl 1:E1618-24. doi: 10.1002/hed.24289. Epub 2015 Nov 28.

PMID:
26614576
15.

Prognostic Implication of Persistent Human Papillomavirus Type 16 DNA Detection in Oral Rinses for Human Papillomavirus-Related Oropharyngeal Carcinoma.

Rettig EM, Wentz A, Posner MR, Gross ND, Haddad RI, Gillison ML, Fakhry C, Quon H, Sikora AG, Stott WJ, Lorch JH, Gourin CG, Guo Y, Xiao W, Miles BA, Richmon JD, Andersen PE, Misiukiewicz KJ, Chung CH, Gerber JE, Rajan SD, D'Souza G.

JAMA Oncol. 2015 Oct;1(7):907-15. doi: 10.1001/jamaoncol.2015.2524.

PMID:
26226294
16.

Chemoradiotherapy-induced upregulation of PD-1 antagonizes immunity to HPV-related oropharyngeal cancer.

Parikh F, Duluc D, Imai N, Clark A, Misiukiewicz K, Bonomi M, Gupta V, Patsias A, Parides M, Demicco EG, Zhang DY, Kim-Schulze S, Kao J, Gnjatic S, Oh S, Posner MR, Sikora AG.

Cancer Res. 2014 Dec 15;74(24):7205-16. doi: 10.1158/0008-5472.CAN-14-1913. Epub 2014 Oct 15.

17.

TGFβ receptor 1: an immune susceptibility gene in HPV-associated cancer.

Levovitz C, Chen D, Ivansson E, Gyllensten U, Finnigan JP, Alshawish S, Zhang W, Schadt EE, Posner MR, Genden EM, Boffetta P, Sikora AG.

Cancer Res. 2014 Dec 1;74(23):6833-44. doi: 10.1158/0008-5472.CAN-14-0602-T. Epub 2014 Oct 1.

18.

Shared VH1-46 gene usage by pemphigus vulgaris autoantibodies indicates common humoral immune responses among patients.

Cho MJ, Lo AS, Mao X, Nagler AR, Ellebrecht CT, Mukherjee EM, Hammers CM, Choi EJ, Sharma PM, Uduman M, Li H, Rux AH, Farber SA, Rubin CB, Kleinstein SH, Sachais BS, Posner MR, Cavacini LA, Payne AS.

Nat Commun. 2014 Jun 19;5:4167. doi: 10.1038/ncomms5167.

19.

Tolerability, toxicity, and temporal implications of transoral robotic surgery (TORS) on adjuvant radiation therapy in carcinoma of the head and neck.

Carpenter TJ, Kann B, Buckstein MH, Ko EC, Bakst RL, Misiukiewicz KJ, Posner MR, Genden EM, Gupta V.

Ann Otol Rhinol Laryngol. 2014 Nov;123(11):791-7. doi: 10.1177/0003489414535560. Epub 2014 May 20.

PMID:
24847162
20.

Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners.

D'Souza G, Gross ND, Pai SI, Haddad R, Anderson KS, Rajan S, Gerber J, Gillison ML, Posner MR.

J Clin Oncol. 2014 Aug 10;32(23):2408-15. doi: 10.1200/JCO.2014.55.1341. Epub 2014 Apr 28.

21.

Reduced impact of nodal metastases as a prognostic factor for tonsil cancer in the HPV era.

Vila PM, Stucken CL, Morris LG, Posner MR, Genden EM, Boffetta P, Sikora AG.

Eur Arch Otorhinolaryngol. 2014 Sep;271(9):2523-9. doi: 10.1007/s00405-013-2796-2. Epub 2013 Nov 5.

22.

Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.

Blanchard P, Bourhis J, Lacas B, Posner MR, Vermorken JB, Cruz Hernandez JJ, Bourredjem A, Calais G, Paccagnella A, Hitt R, Pignon JP; Meta-Analysis of Chemotherapy in Head and Neck Cancer, Induction Project, Collaborative Group.

J Clin Oncol. 2013 Aug 10;31(23):2854-60. doi: 10.1200/JCO.2012.47.7802. Epub 2013 Jul 8.

PMID:
23835714
23.

Trastuzumab for the treatment of salivary duct carcinoma.

Limaye SA, Posner MR, Krane JF, Fonfria M, Lorch JH, Dillon DA, Shreenivas AV, Tishler RB, Haddad RI.

Oncologist. 2013;18(3):294-300. doi: 10.1634/theoncologist.2012-0369. Epub 2013 Feb 21.

24.

Impact of IgA constant domain on HIV-1 neutralizing function of monoclonal antibody F425A1g8.

Yu X, Duval M, Lewis C, Gawron MA, Wang R, Posner MR, Cavacini LA.

J Immunol. 2013 Jan 1;190(1):205-10. doi: 10.4049/jimmunol.1201469. Epub 2012 Nov 26.

25.

Treatment of oropharyngeal squamous cell carcinoma with IMRT: patterns of failure after concurrent chemoradiotherapy and sequential therapy.

Sher DJ, Thotakura V, Balboni TA, Norris CM, Haddad RI, Posner MR, Lorch J, Goguen LA, Annino DJ, Tishler RB.

Ann Oncol. 2012 Sep;23(9):2391-8. doi: 10.1093/annonc/mdr609. Epub 2012 Mar 16.

PMID:
22425872
26.

Acupuncture for dysphagia after chemoradiation in head and neck cancer: rationale and design of a randomized, sham-controlled trial.

Lu W, Wayne PM, Davis RB, Buring JE, Li H, Goguen LA, Rosenthal DS, Tishler RB, Posner MR, Haddad RI.

Contemp Clin Trials. 2012 Jul;33(4):700-11. doi: 10.1016/j.cct.2012.02.017. Epub 2012 Mar 2.

27.

Novel biomarker panel predicts prognosis in human papillomavirus-negative oropharyngeal cancer: an analysis of the TAX 324 trial.

Wu Y, Posner MR, Schumaker LM, Nikitakis N, Goloubeva O, Tan M, Lu C, Iqbal S, Lorch J, Sarlis NJ, Haddad RI, Cullen KJ.

Cancer. 2012 Apr 1;118(7):1811-7. doi: 10.1002/cncr.26485. Epub 2011 Aug 25.

28.

Treatment of oral cavity squamous cell carcinoma with adjuvant or definitive intensity-modulated radiation therapy.

Sher DJ, Thotakura V, Balboni TA, Norris CM Jr, Haddad RI, Posner MR, Lorch J, Goguen LA, Annino DJ, Tishler RB.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e215-22. doi: 10.1016/j.ijrobp.2011.02.023. Epub 2011 Apr 29.

PMID:
21531515
29.

Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial.

Posner MR, Lorch JH, Goloubeva O, Tan M, Schumaker LM, Sarlis NJ, Haddad RI, Cullen KJ.

Ann Oncol. 2011 May;22(5):1071-7. doi: 10.1093/annonc/mdr006. Epub 2011 Feb 11.

30.

Relationship between radiation treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: a subset analysis of TAX 324.

Sher DJ, Posner MR, Tishler RB, Sarlis NJ, Haddad RI, Holupka EJ, Devlin PM.

Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):e813-8. doi: 10.1016/j.ijrobp.2010.12.005. Epub 2011 Feb 6.

PMID:
21300455
31.

Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.

Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, Tan M, Fasciano J, Sammartino DE, Posner MR; TAX 324 Study Group.

Lancet Oncol. 2011 Feb;12(2):153-9. doi: 10.1016/S1470-2045(10)70279-5. Epub 2011 Jan 11.

32.

Efficacy and toxicity of chemoradiotherapy using intensity-modulated radiotherapy for unknown primary of head and neck.

Sher DJ, Balboni TA, Haddad RI, Norris CM Jr, Posner MR, Wirth LJ, Goguen LA, Annino D, Tishler RB.

Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1405-11. doi: 10.1016/j.ijrobp.2010.04.029. Epub 2010 Dec 20.

PMID:
21177045
33.

Salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy.

Schoenfeld JD, Sher DJ, Norris CM Jr, Haddad RI, Posner MR, Balboni TA, Tishler RB.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):308-14. doi: 10.1016/j.ijrobp.2010.09.042. Epub 2010 Nov 13.

PMID:
21075557
34.

Integrating systemic agents into multimodality treatment of locally advanced head and neck cancer.

Posner MR.

Ann Oncol. 2010 Oct;21 Suppl 7:vii246-51. doi: 10.1093/annonc/mdq291. Review.

PMID:
20943623
35.

Acupuncture for dysphagia after chemoradiation therapy in head and neck cancer: a case series report.

Lu W, Posner MR, Wayne P, Rosenthal DS, Haddad RI.

Integr Cancer Ther. 2010 Sep;9(3):284-90. doi: 10.1177/1534735410378856. Epub 2010 Aug 16.

36.

Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer.

Sher DJ, Haddad RI, Norris CM Jr, Posner MR, Wirth LJ, Goguen LA, Annino D, Balboni T, Allen A, Tishler RB.

Cancer. 2010 Oct 15;116(20):4761-8. doi: 10.1002/cncr.25305.

37.

Polymerase chain reaction detection of HPV in squamous carcinoma of the oropharynx.

Agoston ES, Robinson SJ, Mehra KK, Birch C, Semmel D, Mirkovic J, Haddad RI, Posner MR, Kindelberger D, Krane JF, Brodsky J, Crum CP.

Am J Clin Pathol. 2010 Jul;134(1):36-41. doi: 10.1309/AJCP1AAWXE5JJCLZ.

PMID:
20551264
38.

Genetic and epigenetic somatic alterations in head and neck squamous cell carcinomas are globally coordinated but not locally targeted.

Poage GM, Christensen BC, Houseman EA, McClean MD, Wiencke JK, Posner MR, Clark JR, Nelson HH, Marsit CJ, Kelsey KT.

PLoS One. 2010 Mar 11;5(3):e9651. doi: 10.1371/journal.pone.0009651.

39.

Combined antegrade and retrograde esophageal dilation for head and neck cancer-related complete esophageal stenosis.

Goguen LA, Norris CM, Jaklitsch MT, Sullivan CA, Posner MR, Haddad RI, Tishler RB, Burke E, Annino DJ Jr.

Laryngoscope. 2010 Feb;120(2):261-6. doi: 10.1002/lary.20727.

PMID:
19998421
40.

Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120.

Chen L, Kwon YD, Zhou T, Wu X, O'Dell S, Cavacini L, Hessell AJ, Pancera M, Tang M, Xu L, Yang ZY, Zhang MY, Arthos J, Burton DR, Dimitrov DS, Nabel GJ, Posner MR, Sodroski J, Wyatt R, Mascola JR, Kwong PD.

Science. 2009 Nov 20;326(5956):1123-7. doi: 10.1126/science.1175868.

41.

beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial.

Cullen KJ, Schumaker L, Nikitakis N, Goloubeva O, Tan M, Sarlis NJ, Haddad RI, Posner MR.

J Clin Oncol. 2009 Dec 20;27(36):6222-8. doi: 10.1200/JCO.2009.23.0953. Epub 2009 Nov 16.

PMID:
19917838
42.

Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck.

Wirth LJ, Allen AM, Posner MR, Haddad RI, Li Y, Clark JR, Busse PM, Chan AW, Goguen LA, Norris CM, Annino DJ, Tishler RB.

Ann Oncol. 2010 Feb;21(2):342-7. doi: 10.1093/annonc/mdp477. Epub 2009 Nov 5.

PMID:
19892746
43.

Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck.

Parthan A, Posner MR, Brammer C, Beltran P, Jansen JP.

Head Neck. 2009 Oct;31(10):1255-62. doi: 10.1002/hed.21096.

PMID:
19731394
44.

Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck.

Haddad RI, Tishler RB, Norris C, Goguen L, Balboni TA, Costello R, Wirth L, Lorch J, Andreozzi B, Annino D, Posner MR.

J Clin Oncol. 2009 Sep 20;27(27):4448-53. doi: 10.1200/JCO.2009.22.1333. Epub 2009 Aug 24.

PMID:
19704061
45.

Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients.

Settle K, Posner MR, Schumaker LM, Tan M, Suntharalingam M, Goloubeva O, Strome SE, Haddad RI, Patel SS, Cambell EV 3rd, Sarlis N, Lorch J, Cullen KJ.

Cancer Prev Res (Phila). 2009 Sep;2(9):776-81. doi: 10.1158/1940-6207.CAPR-09-0149. Epub 2009 Jul 29.

46.

Induction chemotherapy in head and neck cancer.

Haddad RI, Posner MR.

J Clin Oncol. 2009 Aug 10;27(23):e52-3; author reply e54. doi: 10.1200/JCO.2009.23.7206. Epub 2009 Jul 13. No abstract available.

PMID:
19597015
47.

Genetic variation in the vitamin C transporter, SLC23A2, modifies the risk of HPV16-associated head and neck cancer.

Chen AA, Marsit CJ, Christensen BC, Houseman EA, McClean MD, Smith JF, Bryan JT, Posner MR, Nelson HH, Kelsey KT.

Carcinogenesis. 2009 Jun;30(6):977-81. doi: 10.1093/carcin/bgp076. Epub 2009 Apr 3.

48.

Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation.

Posner MR, Norris CM, Wirth LJ, Shin DM, Cullen KJ, Winquist EW, Blajman CR, Mickiewicz EA, Frenette GP, Plinar LF, Cohen RB, Steinbrenner LM, Freue JM, Gorbunova VA, Tjulandin SA, Raez LE, Adkins DR, Tishler RB, Roessner MR, Haddad RI; TAX 324 Study Group.

Ann Oncol. 2009 May;20(5):921-7. doi: 10.1093/annonc/mdn752. Epub 2009 Jan 29.

PMID:
19179556
49.

A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions.

Wirth LJ, Krane JF, Li Y, Othus M, Moran AE, Dorfman DM, Norris CM Jr, Goguen L, Posner MR, Haddad RI, Bertagnolli MM.

Cancer Prev Res (Phila). 2008 Oct;1(5):339-48. doi: 10.1158/1940-6207.CAPR-07-0003.

50.

Epigenetic profiling reveals etiologically distinct patterns of DNA methylation in head and neck squamous cell carcinoma.

Marsit CJ, Christensen BC, Houseman EA, Karagas MR, Wrensch MR, Yeh RF, Nelson HH, Wiemels JL, Zheng S, Posner MR, McClean MD, Wiencke JK, Kelsey KT.

Carcinogenesis. 2009 Mar;30(3):416-22. doi: 10.1093/carcin/bgp006. Epub 2009 Jan 6.

Supplemental Content

Loading ...
Support Center